-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the successive release of a series of favorable pharmaceutical innovation policies such as speeding up the review and approval of new drugs, as well as the high R&D investment of local innovative drug companies, the continuous breakthroughs in key technologies have made domestic innovative drug companies usher in an intensive harvest period.
The pharmaceutical companies represented by Rui, Fosun Pharma, etc.
have performed impressively, speeding up the start of the competition on the innovative drug track
.
With continuous R&D investment, Hengrui Pharmaceuticals is actively transforming into an innovative drug company
.
According to data from the third quarter report, the company invested 4.
14 billion yuan in research and development in the first three quarters of 2021, an increase of 23.
9% over the same period last year, and its share of revenue increased significantly from 17.
2% in the same period last year, reaching 20.
5%
.
Currently, Hengrui Medicine holds 8 innovative drugs approved for marketing
.
In addition, according to data from Minai.
com, including new drugs introduced through cooperation, Hengrui Medicine currently has 108 innovative drugs (excluding new indications for the development of new drugs on the market) in the clinical application and above stage, of which 81 are Class 1 new drugs
.
A number of blockbuster innovative drugs are about to enter the harvest period, of which 4 new drugs have reached the primary end point in phase III clinical trials, including PD-L1 monoclonal antibody SHR-1316 combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer, antifungal drug SHR8008, and dry eye disease The phase III clinical trials of the drug SHR8058 eye drops and the postoperative pain drug SHR8554 injection have reached the primary endpoint
.
The industry predicts that in the next period of time, Hengrui Pharmaceuticals will usher in the peak period of new drug listing applications
.
BeiGene has already promoted 11 drug candidates into the clinic.
Among them, BTK inhibitor zebutinib, PD-1 antibody drug tislelizumab, and PARP inhibitor pamidarib have been launched.
.
The company’s prospectus shows that as of November 4, 2021, in addition to commercialized drugs and declared drug candidates, the company has 36 drug candidates in clinical research phase and is carrying out more than 50 preclinical research projects, including First-in-class potential HPK1 inhibitors, as well as many other anti-tumor candidates with unique and differentiated designs, such as double antibodies/polyclonal antibodies, PROTAC, ADC, etc.
; including TIGIT, Bcl-2, HPK1, etc.
Many of the research pipelines with differentiated performance have entered key clinical stages one after another
.
In the wave of research and development of innovative drugs in China, Fosun Pharma has continuously launched new drugs in the past two years, including Han Likang, Han Qu You, Handa Yuan, Su Kexin, CAR-T cell therapy products, etc.
, covering small molecules, biological Many fields of medicine and cell therapy
.
It is inseparable from Fosun Pharma's R&D investment that maintains about 15% of its operating income
.
As of the first half of 2021, Fosun Pharma currently has a total of 247 projects in the development of innovative drugs, generic drugs, biosimilar drugs, and generic drug consistency evaluation, among which 18 are small molecule innovative drugs and 25 are bio-innovative drugs, which are licensed to be introduced There are 13 innovative drugs and 19 biosimilar drugs
.
With the gradual listing of innovative products, the company has entered a period of transformation and harvest
.
In addition, CP Tianqing has continuously broadened its product line under research through independent research and development, mergers and acquisitions, and external introductions.
Oncology drugs are the main body, and the research and development pattern of collaborative development in multiple fields such as the digestive system, anti-infection, and respiratory system
.
Since 2019, CP Tianqing Pharmaceuticals has entered an intensive harvest period.
In the past three years, 1 new class 1 drug and 14 first copy approvals have been approved
.
In 2021, Chia Tai Tianqing, a new class 1 drug for the treatment of classic Hodgkin's lymphoma, was approved for marketing, becoming the fifth PD-1 product in China
.
It is reported that in addition to being used for the treatment of classic Hodgkin’s lymphoma, the new indications for NSCLL and nasopharyngeal carcinoma of Paimrizumab have been declared for marketing, and the BLA was submitted to the FDA in May 2021, becoming the third paragraph to be sought in the United States.
Domestically produced PD-1 on the market
.
The pharmaceutical companies represented by Rui, Fosun Pharma, etc.
have performed impressively, speeding up the start of the competition on the innovative drug track
.
With continuous R&D investment, Hengrui Pharmaceuticals is actively transforming into an innovative drug company
.
According to data from the third quarter report, the company invested 4.
14 billion yuan in research and development in the first three quarters of 2021, an increase of 23.
9% over the same period last year, and its share of revenue increased significantly from 17.
2% in the same period last year, reaching 20.
5%
.
Currently, Hengrui Medicine holds 8 innovative drugs approved for marketing
.
In addition, according to data from Minai.
com, including new drugs introduced through cooperation, Hengrui Medicine currently has 108 innovative drugs (excluding new indications for the development of new drugs on the market) in the clinical application and above stage, of which 81 are Class 1 new drugs
.
A number of blockbuster innovative drugs are about to enter the harvest period, of which 4 new drugs have reached the primary end point in phase III clinical trials, including PD-L1 monoclonal antibody SHR-1316 combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer, antifungal drug SHR8008, and dry eye disease The phase III clinical trials of the drug SHR8058 eye drops and the postoperative pain drug SHR8554 injection have reached the primary endpoint
.
The industry predicts that in the next period of time, Hengrui Pharmaceuticals will usher in the peak period of new drug listing applications
.
BeiGene has already promoted 11 drug candidates into the clinic.
Among them, BTK inhibitor zebutinib, PD-1 antibody drug tislelizumab, and PARP inhibitor pamidarib have been launched.
.
The company’s prospectus shows that as of November 4, 2021, in addition to commercialized drugs and declared drug candidates, the company has 36 drug candidates in clinical research phase and is carrying out more than 50 preclinical research projects, including First-in-class potential HPK1 inhibitors, as well as many other anti-tumor candidates with unique and differentiated designs, such as double antibodies/polyclonal antibodies, PROTAC, ADC, etc.
; including TIGIT, Bcl-2, HPK1, etc.
Many of the research pipelines with differentiated performance have entered key clinical stages one after another
.
In the wave of research and development of innovative drugs in China, Fosun Pharma has continuously launched new drugs in the past two years, including Han Likang, Han Qu You, Handa Yuan, Su Kexin, CAR-T cell therapy products, etc.
, covering small molecules, biological Many fields of medicine and cell therapy
.
It is inseparable from Fosun Pharma's R&D investment that maintains about 15% of its operating income
.
As of the first half of 2021, Fosun Pharma currently has a total of 247 projects in the development of innovative drugs, generic drugs, biosimilar drugs, and generic drug consistency evaluation, among which 18 are small molecule innovative drugs and 25 are bio-innovative drugs, which are licensed to be introduced There are 13 innovative drugs and 19 biosimilar drugs
.
With the gradual listing of innovative products, the company has entered a period of transformation and harvest
.
In addition, CP Tianqing has continuously broadened its product line under research through independent research and development, mergers and acquisitions, and external introductions.
Oncology drugs are the main body, and the research and development pattern of collaborative development in multiple fields such as the digestive system, anti-infection, and respiratory system
.
Since 2019, CP Tianqing Pharmaceuticals has entered an intensive harvest period.
In the past three years, 1 new class 1 drug and 14 first copy approvals have been approved
.
In 2021, Chia Tai Tianqing, a new class 1 drug for the treatment of classic Hodgkin's lymphoma, was approved for marketing, becoming the fifth PD-1 product in China
.
It is reported that in addition to being used for the treatment of classic Hodgkin’s lymphoma, the new indications for NSCLL and nasopharyngeal carcinoma of Paimrizumab have been declared for marketing, and the BLA was submitted to the FDA in May 2021, becoming the third paragraph to be sought in the United States.
Domestically produced PD-1 on the market
.
